Capstick, Toby G. D. http://orcid.org/0000-0002-9686-3067
Gudimetla, Sanjay http://orcid.org/0000-0002-3042-2568
Harris, David S. http://orcid.org/0000-0002-3290-3226
Malone, Rachel http://orcid.org/0000-0002-0855-5866
Usmani, Omar S. http://orcid.org/0000-0002-4367-254X
Funding for this research was provided by:
Chiesi Ltd, UK
Article History
Accepted: 20 November 2023
First Online: 10 January 2024
Declarations
:
: This work was initiated and supported by Chiesi Ltd, UK.
: TGDC is a member of the UK Inhaler Group and has received non-financial support from Napp for attendance at ERS conference; TGDC’s employer has received payment for his participation in advisory boards or for providing teaching sessions from AstraZeneca, Chiesi, GSK, Novartis, Boehringer Ingelheim and Insmed, outside the submitted work. SG and RM are employees of Chiesi Ltd, UK. DSH is a member of Drug Delivery to the Lungs organising committee since 2013 (unpaid). OSU reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline; grants from Edmond Pharma; personal fees from NAPP, Mundipharma, Sandoz, Takeda, Cipla, Covis Pharma, Novartis, Mereo BioPharma, OrionPharma, Menarini, UCB, Trudell Medical, Deva Pharmaceuticals, Kamada and Kyorin, outside the submitted work.
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: Not applicable
: All authors contributed to the concept, content and writing of this manuscript.